2. Amyotrophic lateral sclerosis Clinical trials / Disease details
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03580616 (ClinicalTrials.gov) | October 24, 2018 | 26/6/2018 | Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS) | Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis: A Phase IIa Study | Amyotrophic Lateral Sclerosis (ALS) | Drug: L-Serine | Elijah W. Stommel | Brain Chemistry Labs, Institute for Ethnomedicine | Suspended | 18 Years | N/A | All | 50 | Phase 2 | United States |
| 2 | NCT01835782 (ClinicalTrials.gov) | January 2013 | 27/3/2013 | Determining the Safety of L-serine in ALS | Determining the Safety of L-Serine in Subjects With Amyotrophic Lateral Sclerois (ALS) at Varied Doses. | Amyotrophic Lateral Sclerosis (ALS) | Drug: L-Serine | Phoenix Neurological Associates, LTD | Institute for Ethnomedicine | Active, not recruiting | 18 Years | 85 Years | Both | 20 | Phase 1/Phase 2 | United States |